← Back to Home

FDA Clears Gene Therapy for Inherited Childhood Blindness to Enter Clinical Trials; Opus Plans Human Study

OPGx-RDH12 aims to deliver a functional gene to retinal photoreceptor cells, seeking an opportunity to preserve vision that begins to decline in early childhood. Supporting evidence currently comes only from cells and mice; safety and efficacy in humans will be the next test.

By SURL BioNews

For children who begin gradually losing their sight in early childhood because of a genetic defect, a key question in treatment research is whether visual function can be preserved before retinal degeneration progresses further. On October 21, Opus Genetics announced that the U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application for its gene therapy OPGx-RDH12, allowing this concept to advance to testing in humans.

The investigational therapy targets RDH12 gene-related Leber congenital amaurosis (RDH12-LCA). The company plans to initiate a Phase I/II trial in the fourth quarter of 2026; a public summary published by BioWorld the following day also confirmed the clearance and planned timeline. However, IND clearance allows clinical research to proceed; it does not mean the therapy has been approved for marketing, nor does it establish that it can improve vision.

RDH12-LCA is a rare inherited retinal disease. According to company information, mutations in the RDH12 gene impair the function of the associated protein in the retina, causing vision to decline from early childhood and potentially worsen to blindness. The research therefore aims not only to improve vision but also to determine whether further loss can be slowed.

OPGx-RDH12 uses an adeno-associated virus (AAV) vector to deliver a functional copy of the RDH12 gene into retinal photoreceptor cells, attempting to compensate for the functional deficiency caused by the genetic defect. The company said studies in cells and mice have shown restored RDH12 activity and functional improvements. These findings remain preclinical evidence, however, and do not yet establish that patients will receive the same benefits.

Patient families are also helping drive the program. The Global RDH12 Alliance, comprising the U.S.-based RDH12 Fund for Sight and the UK's Eyes on the Future, established a collaboration with Opus in July 2025, committing up to US$1.6 million to support development and participating in clinical and regulatory strategy. This support takes the form of reimbursement for eligible development expenses, subject to agreed development obligations and milestones; it is not unconditional funding that has already been provided in full.

The announcement has not yet provided enough information to fully assess the trial design, including enrollment numbers, the age range of participants, and primary endpoints. It is therefore not yet possible to determine how the study will measure vision preservation or which patients its findings may apply to. BioWorld's publicly available content is also only a brief summary and does not supply these details.

The next substantive developments will be whether the trial begins on schedule and whether human studies can establish acceptable evidence of safety and efficacy. Opus also cautioned that the initiation timeline, treatment effects, and prospects for eventual marketing approval remain uncertain. For patient families, this clearance brings a candidate therapy closer to clinical testing, but several questions still need to be answered before it can become an available treatment.

References

  1. Gund Vision Fund / Opus Genetics
  2. Opus Genetics